Diabetes drug liraglutide linked to lower risk of cardiovascular events

(Karolinska Institutet) Real world data from a large Nordic study shows that use of liraglutide, a drug for type 2 diabetes, is associated with a lower risk of myocardial infarction, stroke or cardiovascular death. The study, led by researchers from Karolinska Institutet in Sweden, is published in The Lancet Diabetes& Endocrinology.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news